English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduWhile CRISPR has shown immense promise as a next-generation therapeutic tool, the gene editing technology’s edits are still imperfect. Researchers have developed a new system to test and analyze CRISPR-based DNA repair and related risks from unintended but harmful “bystander” edits.
Tag: Therapies
Rakuten Medical to Present at 2023 Jefferies London Healthcare Conference on November 14
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023.
Fly Toolkit Created for Investigating COVID-19 Infection Mechanisms
Researchers have created a resource for analyzing how viruses infect human cells. The fruit fly-based toolkit provides a shortcut for assessing SARS-CoV-2 genes and understanding how they interact with human proteins, offering researchers a resource for new COVID-related drug therapies.
SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations
The number of COVID-19 variants is growing rapidly, so much that the scale and scope of mutation may pose a threat to the continuing successful use of the current vaccines and therapies. The findings, by an international team that includes University of California researchers, are being published in the June edition of the peer-reviewed journal EMBO Molecular Medicine. The pace of variation of the SARS-CoV-2 virus strains makes plain the threat that rapidly evolving new strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.
March SLAS Discovery Explores COVID-19 Drug Therapies Six Months Later
The March edition of SLAS Discovery features the cover article, “Therapeutic and Vaccine Options for COVID-19: Status After 6 Months of the Disease Outbreak” by Christian Ogaugwu (Federal University Oye-Ekiti, Ekiti State, Nigeria ), Dawid Maciorowski, Subba Rao Durvasula, Ph.D., Ravi Durvasula, M.D., and Adinarayana Kunamneni, Ph.D. (Loyola University Medical Center, Maywood, IL, USA).
University of Utah to speed process of bringing new therapeutics to patients
The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.
UCLA to lead statewide coalition to address COVID-19’s impact on communities at risk
A coalition of 11 academic institutions and their community partners across California has received a $4.1 million grant from the NIH for a statewide community-engaged approach to addressing COVID-19 among populations that have been disproportionately affected by the pandemic.
Glycans in the SARS-CoV-2 spike protein play active role in infection
As researchers try to develop therapies/vaccines to combat SARS-CoV-2, the coronavirus spike protein is a major focus since it can bind to cells. Now, researchers reporting in ACS Central Science have uncovered an active role for glycans in this process, suggesting targets for vaccines and therapies.